Table 5.
Hazard ratio for kidney outcomes in association with randomization to enalapril for the Prevention Trial
| Enalapril | Placebo | Interaction with time p-value | Period of Follow-up | |||
|---|---|---|---|---|---|---|
| < 6 weeks | 6 weeks to 1 year | > 1 year | ||||
| Creatinine Increase by ≥0.3 mg/dl | ||||||
| Unadjusted HR (95% CI) | 1.22 (1.04, 1.43) | Ref | 0.706 | 1.01 (0.75, 1.36) | 1.62 (1.16, 2.27) | 1.19 (0.95, 1.50) |
| *Adjusted HR (95% CI) | 1.22 (1.04, 1.43) | Ref | 0.638 | 1.01 (0.75, 1.37) | 1.64 (1.17, 2.29) | 1.19 (0.94, 1.49) |
| Decline in eGFR By >30% | ||||||
| Unadjusted HR (95% CI) | 1.21 (1.02, 1.44) | Ref | 0.846 | 0.95 (0.66, 1.36) | 1.50 (1.05, 2.14) | 1.22 (0.97, 1.55) |
| *Adjusted HR (95% CI) | 1.21 (1.02, 1.43) | Ref | 0.990 | 0.95 (0.66, 1.36) | 1.50 (1.05, 2.15) | 1.21 (0.96, 1.53) |
| Decline in eGFR By >40% | ||||||
| Unadjusted HR (95% CI) | 1.28 (0.96, 1.69) | Ref | 0.683 | 1.05 (0.57, 1.90) | 1.40 (0.72, 2.71) | 1.34 (0.93, 1.93) |
| *Adjusted HR (95% CI) | 1.29 (0.97, 1.71) | Ref | 0.871 | 1.05 (0.58, 1.91) | 1.42 (0.73, 2.75) | 1.35 (0.94, 1.96) |
| Incident eGFR<30 ml/min/1.73 m2 | ||||||
| Unadjusted HR (95% CI) | 1.12 (0.67, 1.87) | Ref | 0.352 | 1.19 (0.36, 3.91) | 1.13 (0.41, 3.13) | 1.08 (0.54, 2.17) |
| *Adjusted HR (95% CI) | 1.17 (0.69, 1.98) | Ref | 0.279 | 1.15 (0.35, 3.77) | 1.16 (0.42, 3.20) | 1.18 (0.59, 2.36) |
Analyses performed using Cox proportional hazards ratios. Given significant interaction with time in the Treatment trial, follow-up period was divided into 3 separate intervals of <6-weeks, 6-weeks to 1 year, and >1 year. Even though this interaction with time did not reach significance in the Prevention trial, follow-up period was divided in similar fashion for consistency.
*
Adjusted for age, sex, race, NYHA functional class, current smoking, ischemic etiology of left ventricular dysfunction, diuretic use and baseline eGFR.
eGFR = estimated glomerular filtration rate; HR = hazard ratio; CI = confidence interval; ref=reference